Drugs /

ado-trastuzumab emtansine

Back to Drugs List
Associated Genetic Biomarkers
Associated Diseases

Overview

Generic Name(s):
ado-trastuzumab emtansine
Trade Name(s):
Kadcyla
NCI Definition [1]:
An antibody-drug conjugate (ADC) consisting of the recombinant anti-epidermal growth factor receptor 2 (HER2) monoclonal antibody trastuzumab conjugated to the maytansinoid DM1 via a nonreducible thioether linkage (MCC) with potential antineoplastic activity. The trastuzumab moiety of this ADC binds to HER2 on tumor cell surfaces; upon internalization, the DM1 moiety is released and binds to tubulin, thereby disrupting microtubule assembly/disassembly dynamics and inhibiting cell division and the proliferation of cancer cells that overexpress HER2. Linkage of antibody and drug through a nonreducible linker has been reported to contribute to the improved efficacy and reduced toxicity of this ADC compared to similar ADCs constructed with reducible linkers.

Biomarker-Directed Therapies

Clinical Trials

View Clinical Trials for ado-trastuzumab emtansine

Ado-trastuzumab emtansine has been investigated in 52 clinical trials, of which 38 are open and 14 are closed. Of the trials investigating ado-trastuzumab emtansine, 13 are phase 1 (7 open), 8 are phase 1/phase 2 (5 open), 22 are phase 2 (18 open), and 9 are phase 3 (8 open).

ERBB2 Amplification, HER2 Positive, and HER2 Overexpression are the most frequent biomarker inclusion criteria for ado-trastuzumab emtansine clinical trials.

Breast carcinoma, invasive breast carcinoma, and malignant solid tumor are the most common diseases being investigated in ado-trastuzumab emtansine clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Ado-Trastuzumab Emtansine
Top Biomarker Inclusion Criteria for Closed Clinical Trials Investigating Ado-Trastuzumab Emtansine
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating ado-trastuzumab emtansine and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
pro132365, t-dm1, Kadcyla, t-dm1 cpd, trastuzumab-dm1, trastuzumab-mcc-dm1 immunoconjugate, ado-trastuzumab emtansine, trastuzumab-mcc-dm1 antibody-drug conjugate, ado trastuzumab emtansine, ro5304020, trastuzumab-dm1, trastuzumab emtansine, trastuzumab-mcc-dm1 immunoconjugate, trastuzumab-dm1 conjugate, kadcyla, trastuzumab emtansine, trastuzumab-mcc-dm1 antibody-drug conjugate, trastuzumab-mcc-dm1, trastuzumab emtansine, trastuzumab-mcc-dm1, trastuzumab emtansine, immunoglobulin g1, anti-(human p185neu receptor) (human-mouse monoclonal rhumab her2 gamma1-chain), disulfide with human-mouse monoclonal rhumab her2 light chain, dimer, tetraamide with n2'-(3-((1-((4-carboxycyclohexyl)methyl)-2,5-dioxo-3-pyrrolidinyl)thio)-1-oxopropyl)-n2'-deacetylmaytansine, trastuzumab emtansine (substance), ado-trastuzumab emtansine, ado trastuzumab emtansine
Drug Categories [2]:
Therapeutic antibodies
Drug Target(s) [2]:
ERBB2
NCIT ID [1]:
C82492
SNOMED ID [1]:
R-FB9FC

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.